Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine

- More than 40 Customers Including Pfizer, BMS, EMD Serono, Novartis, NIH, Broad Institute, Harvard University to Present on Sequencing, Drug Discovery, Biologics and Vaccine Development, In Vivo Imaging and Pre-Clinical Tissue Imaging -

HOPKINTON, Mass., May 5, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery and life sciences research for personalized medicine, will be hosting its Caliper Owners Group (COG 2011) meeting on May 17th and 18th.  This annual event brings together global thought-leaders in research, drug discovery, and diagnostics to discuss the technologies and discoveries that are transforming the detection and treatment of disease, and making personalized medicine a reality.

"COG 2011 will be a landmark event for Caliper," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences.  "The presentations and groundbreaking research that will be shared at this event will highlight how Caliper technologies are increasingly impacting the development of therapeutics and diagnostics that will revolutionize medicine and enable personalized healthcare."

Over 375 customers and investors are expected to attend the meeting, which will be held at Caliper's Hopkinton headquarters. The event will feature keynote presentations from Dr. Dennis Ausiello, Physician-in-Chief, Department of Medicine, Massachusetts General Hospital, Jackson Professor of Clinical Medicine, Harvard Medical School, Chief Scientific Officer, Partners Healthcare; Dr. Go van Dam, Associate Professor at University Medical Center Groningen; Dr. Stephan Schuster, Professor of Biochemistry and Molecular Biology at Pennsylvania State University; and Kevin Hrusovsky, President and CEO of Caliper Life Sciences.  Additionally, the event will feature more than 40 presentations from researchers representing life sciences companies and institutions, including Pfizer, Novartis, Bristol Meyers Squibb, University of Washington Genome Institute, University of Miami Hussman Institute for Human Genomics, University of Sherbrooke, Children's Mercy Hospital, EMD Serono, Cell Signaling Technology, Yale University, Transgenomic, Access Genetics, Roche NimbleGen, NuGEN Technologies, and the National Institutes of Health.

To view the complete agenda or register to attend, please visit Caliper's website at: http://www.caliperls.com/products/cog2011.php

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease.  Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper is a registered trademark of Caliper Life Sciences, Inc.

SOURCE Caliper Life Sciences, Inc.

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.